文献速递乳腺癌放疗放疗物理与技术

早期乳腺癌根治性大分割放疗:立体定向消融放疗与质子束治疗完整乳腺肿瘤的剂量学可行性

Definitive hypofractionated radiation therapy for early stage breast cancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breast tumors.
PubMed 文献 · Adv Radiat Oncol · 2018-06-11

针对医学上无法手术或拒绝手术的早期乳腺癌老年患者,本研究对15例经活检证实、术前CT可见肿瘤的患者进行剂量学分析,比较三维适形放疗、立体定向消融放疗和质子束治疗给予50 Gy/5次的大分割方案。结果显示立体定向消融放疗和质子束治疗靶区覆盖良好,正常结构剂量约束多数可达到,但部分病例皮肤或胸壁剂量约束超标,取决于肿瘤解剖位置。

要点

  • 立体定向消融放疗和质子束治疗对早期乳腺癌行50 Gy/5次大分割放疗在剂量学上可行。
  • 皮肤或胸壁剂量约束在部分立体定向消融放疗和质子束治疗计划中超标,取决于肿瘤解剖位置。
  • 三种技术靶区覆盖均优,立体定向消融放疗和质子束治疗较三维适形放疗有剂量学改善。

核心结论

  • 立体定向消融放疗和质子束治疗用于早期乳腺癌根治性大分割放疗在剂量学上似乎可行。
  • 肿瘤相对于皮肤和胸壁的解剖位置似乎是主要的剂量学限制因素。

研究设计与样本

  • 剂量学研究纳入15例经活检证实、术前CT可见肿瘤的早期乳腺癌患者。
  • 勾画大体肿瘤体积并与既往影像证实的恶性病变对应,基于摆位不确定性和影像引导能力创建治疗边界。
  • 比较三维适形放疗、立体定向消融放疗和质子束治疗三种技术给予50 Gy/5次方案的剂量体积直方图。

主要发现

  • 立体定向消融放疗、质子束治疗和三维适形放疗的中位计划靶体积分别为11.91、21.03和45.08 cm³,三种治疗模式间有显著差异(P < .0001)。
  • 三种模式对大体肿瘤和临床靶区的总体覆盖均优。
  • 立体定向消融放疗和质子束治疗各自以独特方式相对三维适形放疗显示出显著剂量学改善。
  • 使用立体定向消融放疗和质子束治疗时,对正常结构包括同侧/对侧乳腺、双侧肺和心脏的剂量约束均持续达到。
  • 部分立体定向消融放疗和质子束治疗计划的皮肤或胸壁剂量约束超标,由肿瘤解剖位置决定。

关键数值与推荐

  • 处方总剂量为50 Gy分5次。
  • 立体定向消融放疗、质子束治疗和三维适形放疗的中位计划靶体积分别为11.91、21.03和45.08 cm³(P < .0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Few definitive treatment options exist for elderly patients diagnosed with early stage breast cancer who are medically inoperable or refuse surgery. Historical data suggest very poor local control with hormone therapy alone. We examined the dosimetric feasibility of hypofractionated radiation therapy using stereotactic ablative radiotherapy (SABR) and proton beam therapy (PBT) as a means of definitive treatment for early stage breast cancer. METHODS AND MATERIALS: Fifteen patients with biopsy-proven early stage breast cancer with a clinically visible tumor on preoperative computed tomography scans were identified. Gross tumor volumes were contoured and correlated with known biopsy-proven malignancy on prior imaging. Treatment margins were created on the basis of set-up uncertainty and image guidance capabilities of the three radiation modalities analyzed (3-dimensional conformal radiation therapy [3D-CRT], SABR, and PBT) to deliver a total dose of 50 Gy in 5 fractions. Dose volume histograms were analyzed and compared between treatment techniques. RESULTS: The median planning target volume (PTV) for SABR, PBT, and 3-dimensional CRT was 11.91, 21.03, and 45.08 cm3, respectively, and were significantly different (P < .0001) between treatment modalities. Overall target coverage of gross tumor and clinical target volumes was excellent with all three modalities. Both SABR and PBT demonstrated significant dosimetric improvements, each in its own unique manner, relative to 3D-CRT. Dose constraints to normal structures including ipsilateral/contralateral breast, bilateral lungs, and heart were all consistently achieved using SABR and PBT. However, skin or chest wall dose constraints were exceeded in some cases for both SABR and PBT plans and was dictated by the anatomic location of the tumor. CONCLUSIONS: Definitive hypofractionated radiation therapy using SABR and PBT appears to be dosimetrically feasible for the treatment of early stage breast cancer. The anatomical location of the tumor relative to the skin and chest wall appears to be the primary limiting dosimetric factor.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lischalk JW, Chen H, Repka MC, et al. Definitive hypofractionated radiation therapy for early stage breast cancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breast tumors. Adv Radiat Oncol. 2018. PMID: 30202812. doi:10.1016/j.adro.2018.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。